PRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27Kip1

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Nicholas, Courtney ^a   Yang, Jennifer ^a   Peters, Sara B ^a   Bill, Matthew A ^a   Baiocchi, Robert A ^a   Yan, Fengting ^a   Sïf, Saïd ^b   Tae, Sookil ^b   Gaudio, Eugenio ^b   Wu, Xin ^a   Grever, Michael R ^a   Young, Gregory S ^a   Lesinski, Gregory B ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 5; PROTEIN MEP50; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL FRACTIONATION; CELL PROLIFERATION; CONTROLLED STUDY; CUTANEOUS MELANOMA; EPIDERMIS; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KERATINOCYTE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA CELL; METASTATIC MELANOMA; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; EPIDERMIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; MICE, NUDE; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NEOPLASM METASTASIS; PROTEIN-ARGININE N-METHYLTRANSFERASES;

EID: 84884765018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074710     Document Type: Article

References (60)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Krause CD, Yang ZH, Kim YS, Lee JH, Cook JR, et al. (2007) Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Ther 113: 50-87.
4. Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST, et al. (2007) Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J 26: 3558-3569.
5. Pal S, Sif S, (2007) Interplay between chromatin remodelers and protein arginine methyltransferases. J Cell Physiol 213: 306-315.
6. Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS, (2011) Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res 71: 5579-5587.
7. Wang L, Pal S, Sif S, (2008) Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol 28: 6262-6277.
8. Yan F. (2010) Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas; abstract #1584; American Association for Cancer Research 2010 Annual Meeting; Apr 17-21, 2010 Washington, DC.
9. Gu Z, Gao S, Zhang F, Wang Z, Ma W, et al. (2012) Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J.
10. Gu Z, Li Y, Lee P, Liu T, Wan C, et al. (2012) Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One 7: e44033.
11. Wei TY, Juan CC, Hisa JY, Su LJ, Lee YC, et al. (2012) Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci 103: 1640-1650.
12. Bao X, Zhao S, Liu T, Liu Y, Yang X, (2013) Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem 61: 206-217.
13. Bruns AF, Grothe C, Claus P, (2009) Fibroblast growth factor 2 (FGF-2) is a novel substrate for arginine methylation by PRMT5. Biol Chem 390: 59-65.
14. Durant ST, Cho EC, La Thangue NB, (2009) p53 methylation - the Arg-ument is clear. Cell Cycle 8: 801-802.
15. Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, et al. (2008) Arginine methylation regulates the p53 response. Nat Cell Biol 10: 1431-1439.
16. Lacroix M, El Messaoudi S, Rodier G, Le Cam A, Sardet C, et al. (2008) The histone-binding protein COPR5 is required for nuclear functions of the protein arginine methyltransferase PRMT5. EMBO Rep 9: 452-458.
17. Nagamatsu G, Kosaka T, Kawasumi M, Kinoshita T, Takubo K, et al. (2011) A germ cell-specific gene, Prmt5, works in somatic cell reprogramming. J Biol Chem 286: 10641-10648.
18. Andreu-Perez P, Esteve-Puig R, de Torre-Minguela C, Lopez-Fauqued M, Bech-Serra JJ, et al. (2011) Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal 4: ra58.
19. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, et al. (2007) Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 67: 3239-3253.
20. Chuang TW, Peng PJ, Tarn WY, (2011) The exon junction complex component Y14 modulates the activity of the methylosome in biogenesis of spliceosomal small nuclear ribonucleoproteins. J Biol Chem 286: 8722-8728.
21. Feng Y, Wang J, Asher S, Hoang L, Guardiani C, et al. (2011) Histone H4 acetylation differentially modulates arginine methylation by an in Cis mechanism. J Biol Chem 286: 20323-20334.
22. He W, Ma X, Yang X, Zhao Y, Qiu J, et al. (2011) A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage. Nucleic Acids Res 39: 4719-4727.
23. Hsu JM, Chen CT, Chou CK, Kuo HP, Li LY, et al. (2011) Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol 13: 174-181.
24. Jung GA, Shin BS, Jang YS, Sohn JB, Woo SR, et al. (2011) Methylation of eukaryotic elongation factor 2 induced by basic fibroblast growth factor via mitogen-activated protein kinase. Exp Mol Med 43: 550-560.
25. Liu F, Zhao X, Perna F, Wang L, Koppikar P, et al. (2011) JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19: 283-294.
26. Tee WW, Pardo M, Theunissen TW, Yu L, Choudhary JS, et al. (2010) Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev 24: 2772-2777.
27. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
28. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, et al. (2005) Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433: 764-769.
29. Loercher AE, Tank EM, Delston RB, Harbour JW, (2005) MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 168: 35-40.
30. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, et al. (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 20: 3426-3439.
31. Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, Tweardy DJ, et al. (1999) Systemic interferon-alpha (IFN-α) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med 5: 11-20.
32. Loewe R, Kittler H, Fischer G, Fae I, Wolff K, et al. (2004) BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol 123: 733-736.
33. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20.
34. Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, et al. (2010) Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 18: 329-340.
35. Friesen WJ, Wyce A, Paushkin S, Abel L, Rappsilber J, et al. (2002) A novel WD repeat protein component of the methylosome binds Sm proteins. J Biol Chem 277: 8243-8247.
36. Guo SL, Peng Z, Yang X, Fan KJ, Ye H, et al. (2011) miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. Int J Biol Sci 7: 567-574.
37. Haflidadottir BS, Bergsteinsdottir K, Praetorius C, Steingrimsson E, (2010) miR-148 regulates Mitf in melanoma cells. PLoS One 5: e11574.
38. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, et al. (2008) Chromatin structure analyses identify miRNA promoters. Genes Dev 22: 3172-3183.
39. Wang B, Li W, Guo K, Xiao Y, Wang Y, et al. (2012) miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 421: 4-8.
40. Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, et al. (2001) Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 104: 731-741.
41. Pollack BP, Kotenko SV, He W, Izotova LS, Barnoski BL, et al. (1999) The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J Biol Chem 274: 31531-31542.
42. Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, et al. (2009) PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res 7: 557-569.
43. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S, (2004) Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 24: 9630-9645.
44. Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, et al. (2003) mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol 23: 7475-7487.
45. Scoumanne A, Zhang J, Chen X, (2009) PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res 37: 4965-4976.
46. Yan F, Smith P, Alinari L, Ryu J, Yu B, et al. (2011) Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma. ASH Annual Meeting Abstracts 118: abstract #595.
47. Majumder S, Alinari L, Roy S, Miller T, Datta J, et al. (2010) Methylation of histone H3 and H4 by PRMT5 regulates ribosomal RNA gene transcription. J Cell Biochem 109: 553-563.
48. Budden T, Bowden NA, (2013) The Role of Altered Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanomagenesis. Int J Mol Sci 14: 1132-1151.
49. Handoko HY, Rodero MP, Boyle GM, Ferguson B, Engwerda C, et al. (2013) UVB-Induced Melanocyte Proliferation in Neonatal Mice Driven by CCR2-Independent Recruitment of Ly6c(low)MHCII(hi) Macrophages. J Invest Dermatol 133: 1803-1812.
50. Wang W, Edington HD, Rao UN, Jukic DM, Wang H, et al. (2008) STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNα therapy. J Invest Dermatol 128: 1997-2002.
51. Kanade SR, Eckert RL, (2012) Protein arginine methyltransferase 5 (PRMT5) signaling suppresses protein kinase Cδ- and p38δ-dependent signaling and keratinocyte differentiation. J Biol Chem 287: 7313-7323.
52. Terris DJ, Dunphy EP, (1994) Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg 120: 283-287.
53. Hartmann A, Kunz M, Kostlin S, Gillitzer R, Toksoy A, et al. (1999) Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 59: 1578-1583.
54. Hemesath TJ, Steingrimsson E, McGill G, Hansen MJ, Vaught J, et al. (1994) microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 8: 2770-2780.
55. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, et al. (2011) Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30: 2307-2318.
56. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, et al. (2008) Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 3: e2734.
57. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, et al. (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66: 9483-9491.
58. Bill MA, Fuchs JR, Li C, Yui J, Bakan C, et al. (2010) The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 9: 165.
59. Lesinski GB, Raig ET, Guenterberg K, Brown L, Go MR, et al. (2008) IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res 68: 8351-8360.
60. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.